Gemini Therapeutics, Inc. reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported net loss was USD 18.55 million compared to USD 10 million a year ago. Basic loss per share from continuing operations was USD 0.43 compared to USD 0.65 a year ago. For the nine months, net loss was USD 54.05 million compared to USD 26.52 million a year ago. Basic loss per share from continuing operations was USD 1.37 compared to USD 1.77 a year ago.